GlassScriptPhysician profile
Anuradha Kunthur
NPI 1770526147
$3,904.78
in general payments reported to CMS, 2019-2025
42 companies · $93.64 in 2025
The $93.64 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,290 · 2023: $2,096 · 2024: $425 · 2025: $93.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,614.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,614.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $592.92 | 2022-2024 | |
| Lilly USA, LLC | $219.05 | 2022-2023 | Jaypirca, Retevmo, Verzenio |
| Merck Sharp & Dohme LLC | $216.80 | 2022-2023 | Keytruda, Lynparza |
| Astrazeneca Pharmaceuticals LP | $206.76 | 2022-2023 | Enhertu, Tagrisso, Lynparza |
| Pfizer INC. | $200.18 | 2022-2024 | |
| Amgen INC. | $194.20 | 2022-2023 | Lumakras, Kyprolis, Vectibix |
| E.R. Squibb & Sons, L.L.C. | $183.02 | 2022-2023 | Opdivo, Opdualag |
| Astellas Pharma US INC | $168.42 | 2022-2024 | Padcev, Xospata |
| Abbvie INC. | $139.05 | 2023-2024 | |
| Seagen INC. | $134.43 | 2022-2023 | Adcetris, Tukysa |
| Eisai INC. | $127.35 | 2022-2023 | |
| Incyte Corporation | $118.25 | 2022-2023 | Jakafi, Monjuvi |
| Genzyme Corporation | $112.37 | 2022-2024 | |
| Genentech USA, INC. | $103.91 | 2022-2023 | Lunsumio, Polivy, Gazyva |
| Novo Nordisk INC | $93.64 | 2025 | Wegovy |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $88.56 | 2022-2023 | Imbruvica |
| Celgene Corporation | $86.26 | 2022-2023 | Reblozyl, Pomalyst |
| Beigene USA, INC. | $68.90 | 2022-2024 | Brukinsa |
| Ipsen Biopharmaceuticals, INC | $65.55 | 2022-2023 | Somatuline Depot, Onivyde, Tazverik |
| Emd Serono, INC. | $60.58 | 2022-2023 | Bavencio |
| Janssen Biotech, INC. | $55.33 | 2022-2023 | Imbruvica, Darzalex |
| Exelixis INC. | $53.44 | 2022-2024 | Cabometyx |
| Gilead Sciences, INC. | $49.83 | 2022-2023 | Trodelvy |
| Morphosys, US INC. | $48.40 | 2023 | Monjuvi |
| Glaxosmithkline, LLC. | $47.49 | 2023 | Zejula, Jemperli, Ojjaara |
| Aveo Pharmaceuticals, INC. | $39.75 | 2022-2023 | Fotivda |
| Regeneron Healthcare Solutions, INC. | $38.13 | 2023 | Libtayo |
| Mirati Therapeutics, INC. | $38.10 | 2023 | Krazati |
| Puma Biotechnology, INC. | $37.54 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.29 | 2023 | |
| Pharmaessentia USA Corporation | $32.91 | 2022-2023 | Besremi |
| G1 Therapeutics, INC. | $32.60 | 2022-2023 | Cosela |
| Karyopharm Therapeutics INC. | $31.52 | 2023 | Xpovio |
| Rigel Pharmaceuticals, INC. | $30.91 | 2022 | |
| Servier Pharmaceuticals LLC | $30.50 | 2023 | |
| Daiichi Sankyo INC. | $20.35 | 2023 | Enhertu |
| Pharmacosmos Therapeutics INC. | $19.91 | 2023 | Monoferric |
| Sobi, INC | $19.87 | 2023 | |
| Array Biopharma INC | $19.65 | 2023 | Lorbrena, Braftovi, Mektovi |
| Adc Therapeutics America, INC. | $15.89 | 2023 | |
| Amag Pharmaceuticals, INC. | $14.98 | 2022 | |
| Stemline Therapeutics INC. | $13.19 | 2023 | Orserdu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anuradha Kunthur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.